7 papers in the library · 146 citations · publishing 2023-2025
The Journal of Clinical Psychiatry October 13, 2025 Pim B. van der Meer, Sebastiaan O Verboeket, Arjen J. C. Slooter et al.
Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to evaluate the efficacy and safety of ketamine and esketamine for catatonia.
Psychedelic Medicine October 8, 2025 Pim B. van der Meer, Nout Schukking, Miranda G. Dik et al.
Background: Psychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available...
Clinical Pharmacokinetics February 21, 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. correction
Correction to: Clinical Pharmacokinetics (2025) 64:53–66 https://doi.org/10.1007/s40262-024-01454-4 In the original version of this article, the given and family names of J. G. Coen van Hasselt were incorrectly structured as Coen J.G. van Hasselt. The correct name should read as given name: J. G. Coen and family name: van Hasselt.
Clinical Pharmacokinetics February 1, 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al. 7 citations
N,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT. Clinical studies that administered known amounts of DMT and reported PK data and/or...
Clinical Pharmacokinetics 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. 20 citations
Overall, we found the pharmacokinetic parameters of psilocin to be consistent between studies. This review may guide the further clinical development of psilocybin-based therapies.
Leiden Repository (Leiden University) 2025 Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones et al.
BACKGROUND AND OBJECTIVE\nMETHODS\nRESULTS\nCONCLUSION\nN,N-Dimethyltryptamine (DMT) is currently being studied for its therapeutic potential in various psychiatric disorders. An understanding of its pharmacokinetics (PK) is essential to determine appropriate dose ranges in future clinical studies. We conducted a systematic literature review on the PK of DMT.\nClinical studies that administered...
Frontiers in Psychiatry February 9, 2023 Kees Kramers, Arnt Schellekens, Metten Somers et al. 119 citations
Background Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted...